Aeterna Zentaris Inc. (NASDAQ:AEZS) a late-stage biopharmaceutical company that engages in the discovery, development, and commercialization of drugs for oncology and endocrine therapy is up (+7.94%) on higher than average volume of 1,478,415 shares traded. Aeterna Zentaris Inc. (NASDAQ:AEZS) has been trending higher over the last quarter after bouncing off of it's 52-week low of $1.75 as more and more investors look to Biotech companies for above average gains. This current up trend in the stock has prompted Growing Stock Report to add Aeterna Zentaris Inc. (NASDAQ:AEZS) to their Biotech Watch List.
Click Here to find out what other Investors are saying about Aeterna Zentaris Inc. (NASDAQ:AEZS)
OXiGENE, Inc. (NASDAQ:OXGN) a clinical-stage biopharmaceutical company that develops therapeutics to treat cancer and eye diseases is currently up (+19.14%) on over 1,090,593 shares traded after announcing this week that the randomized Phase 2 study evaluating the combination of ZYBRESTAT(R) (fosbretabulin tromethamine or CA4P) and Avastin(R) (bevacizumab) to treat patients with persistent or recurrent ovarian cancer has again demonstrated acceptable tolerability in the second and final scheduled interim toxicity analysis. OXiGENE, Inc. (NASDAQ:OXGN) hit a daily high of $5.90 today and is still holding on to its gains made this week which has prompted Growing Stock Report to add the stock to their Biotech Watch List.
Click here to see the Trend and Investor Poll OXiGENE, Inc.
GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.
Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed.
Timing is important when trading Small Caps and Penny Stocks.
Simply sign up for free and start receiving exclusive alerts.Subscribe Here: http://www.GrowingStockReport.com
Disclosure: GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.
Contact Info:Growing Stock Reporteditor@GrowingStockReport.com